Henagliflozin
drugOn this page
Also known as SHR-3824Shr3824
Summary
Henagliflozin (CHEMBL4297431) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including atrial fibrillation and type 2 diabetes mellitus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 23
- Chemistry: 454.9 Da · C22H24ClFO7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297431 |
| Name | Henagliflozin |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 56832738 |
| Molecular formula | C22H24ClFO7 |
| Molecular weight | 454.9 |
| InChIKey | HYTPDMFFHVZBOR-VNXMGFANSA-N |
SMILES: CCOC1=C(C=C(C=C1)CC2=C(C=CC(=C2)[C@]34[C@@H]([C@H]([C@@H]([C@](O3)(CO4)CO)O)O)O)Cl)F
IUPAC name: (1R,2S,3S,4R,5R)-5-[4-chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
Also known as: Henagliflozin, SHR-3824, Shr3824, SHR3824, HENAGLIFLOZIN
Patent coverage: 62 distinct patent families (140 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 131 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Sodium/glucose cotransporter 2, Sodium/glucose cotransporter 1.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| SLC5A2 | 8.62 | IC50 | 2.38 | nM | CHEMBL_ACT_29054651 |
| SLC5A1 | 5.36 | IC50 | 4324 | nM | CHEMBL_ACT_29054652 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
Clinical trials
Total trials: 23.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 11 |
| PHASE4 | 5 |
| Not specified | 5 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06216340 | PHASE4 | NOT_YET_RECRUITING | Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes |
| NCT06448130 | PHASE4 | NOT_YET_RECRUITING | Henagliflozin’s Impact on Prediabetes Remission |
| NCT05677334 | PHASE4 | COMPLETED | Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM |
| NCT06187727 | PHASE4 | COMPLETED | Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction |
| NCT06218342 | PHASE4 | UNKNOWN | Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease |
| NCT03159052 | PHASE3 | UNKNOWN | Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes |
| NCT04390295 | PHASE3 | UNKNOWN | Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes |
| NCT02346175 | PHASE1 | COMPLETED | Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients |
| NCT02353975 | PHASE1 | COMPLETED | Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects |
| NCT02354027 | PHASE1 | COMPLETED | The Drug-drug Interaction of SHR3824 and Metformin |
| NCT02356224 | PHASE1 | COMPLETED | The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers |
| NCT02361138 | PHASE1 | COMPLETED | The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers |
| NCT02366351 | PHASE1 | UNKNOWN | The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients |
| NCT02366377 | PHASE1 | UNKNOWN | The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients |
| NCT02500485 | PHASE1 | UNKNOWN | The Drug-drug Interaction of SHR3824 and SP2086 |
| NCT03159832 | PHASE1 | UNKNOWN | Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient |
| NCT03160014 | PHASE1 | UNKNOWN | Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment |
| NCT03329118 | PHASE1 | UNKNOWN | Drug-drug Interaction Between Simvastatin and SHR3824 |
| NCT07294495 | Not specified | NOT_YET_RECRUITING | Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR |
| NCT05742230 | Not specified | UNKNOWN | Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF) |
| NCT06031389 | Not specified | UNKNOWN | Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis |
| NCT06059287 | Not specified | UNKNOWN | The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics |
| NCT06085703 | Not specified | COMPLETED | Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: atrial fibrillation, type 2 diabetes mellitus